Previous 10 | Next 10 |
Minerva Neurosciences press release (NASDAQ:NERV): Q4 GAAP EPS of -$0.50 misses by $0.31. Cash, equivalents and restricted cash as of December 31, 2021 were approximately $60.9 million, as compared to $25.5 million at December 31, 2020. For further details see: Minerva Neurosciences GAA...
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today reported key business updates and financial results fo...
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that results from the Phase 3 clinical trial of r...
Minerva Neurosciences, Inc. (NERV) Q3 2021 Results Earnings Conference Call November 8, 2021, 08:30 AM ET Company Participants Geoff Race - President Remy Luthringer - Chief Executive Officer Frederick Ahlholm - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Thom...
Minerva Neurosciences (NASDAQ:NERV): Q3 GAAP EPS of -$0.22 misses by $0.01 Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2021 were approximately $65.7M. Shares +9.67% PM Press Release For further details see: Minerva Neurosciences EPS mi...
Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, tod...
Minerva Neurosciences (NASDAQ:NERV) is scheduled to announce Q3 earnings results on Monday, November 8th, before market open. The consensus EPS Estimate is -$0.22 (-15.8% Y/Y) and the consensus Revenue Estimate is $0.2M Over the last 3 months, EPS estimates have seen 1 upward revision and 2 d...
AVDL, AXSM, BKI, COTY, CTRE, DS,EDIT, EHTH, IMOS, KOS, LINC, LTBR, MTNB, NERV, OCN, PSEC, RDUS, RETA, TGLS, THS, TSEM, TTD, TYME, USFD, VAC, VTRS, WOW For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
Minerva Neurosciences (NASDAQ:NERV) shares fall 4% premarket after the U.S. FDA denied the company’s request for a pre-NDA meeting for roluperidone. The health regulator responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of rolu...
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U. S. Food and Drug Administration (FDA)...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to ...
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Helix Energy posted ...